Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,035 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Soft Tissue Neoplasms Clear all

Conditions: Uterine Fibroids
Interventions: 25 mg Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tecogalan sodium; Drug
Lead sponsor: Daiichi Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neuroblastoma, Sarcoma
Interventions: aldesleukin, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, therapeutic autologous lymphocytes; Biological
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Year to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
Interventions: GVAX; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Sarcoma
Interventions: PM01183, Doxorubicin, Gemcitabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Soft Tissue Sarcoma
Interventions: Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Santa Monica, California • Coeur d'Alene, Idaho • Omaha, Nebraska

Conditions: Uterine Fibroids
Interventions: 12.5 mg Proellex, 25 mg Proellex, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more

Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions: LY2880070, Gemcitabine; Drug
Lead sponsor: Esperas Pharma Inc.; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, paclitaxel, topotecan hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 39 more

Conditions: Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions: filgrastim, docetaxel; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 26 more

Conditions: Sarcoma
Interventions: Gemcitabine, Docetaxel and Bevacizumab; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions: MRI IMAGING; Diagnostic Test
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pleuropulmonary Blastoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Synovial Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Lorvotuzumab Mertansine, Pharmacological Study; Other · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 30 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more

Conditions: Malignant Skin Tumor, Soft Tissue Tumor, Malignant
Interventions: Diffusing Alpha-emitter Radiation Therapy; Radiation
Lead sponsor: Alpha Tau Medical LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Des Moines, Iowa • New York, New York • Germantown, Tennessee + 2 more

Conditions: Pediatric Solid Tumors
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Soft Tissue Sarcoma, Bone Sarcoma
Interventions: Cyclophosphamide, attIL2-T cells; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma
Interventions: pazopanib; Drug
Lead sponsor: Vector Oncology; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 9
States / cities: Santa Monica, California • Washington D.C., District of Columbia • Post Falls, Idaho + 6 more

Conditions: Sarcoma
Interventions: gene expression analysis, polymerase chain reaction, western blotting, neoadjuvant therapy, therapeutic conventional surgery, intensity-modulated radiation therapy; Genetic · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sarcoma
Interventions: cisplatin, ifosfamide, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 21 Years to 120 Years · Female only
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Gatos, California + 56 more

Conditions: Melanoma, Soft Tissue Sarcoma
Interventions: Autologous total tumor mRNA loaded DOTAP liposome vaccine; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Kaposi's Sarcoma
Interventions: Tc 99m tilmanocept; Drug
Lead sponsor: Navidea Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions: Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more

Conditions: Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions: Docetaxel, Gemcitabine, Hydroxychloroquine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Soft Tissue Sarcoma
Interventions: proton radiation, surgery (wide local excision; limb preservation surgery); Radiation · Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 98 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Docetaxel in Treating Children With Recurrent Solid Tumors

Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

Serial MRI Scans During Radiation Therapy

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors

Molecular Analysis Of Solid Tumors

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall